Skip to Main Content
Our Commitment to Diversity

K&L Gates Team Backs $310 Million Pharma Deal

17 February 2016

After nearly a year of negotiations, our corporate / M&A practice recently completed a complex US$310 million acquisition for NeoGenomics Inc., a cancer genetics diagnostic company, of Clarient, Inc., a General Electric Health Care Life Sciences unit.

Read the article in the Daily Business Review.

Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel